CO2018002534A2 - Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos - Google Patents
Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticosInfo
- Publication number
- CO2018002534A2 CO2018002534A2 CONC2018/0002534A CO2018002534A CO2018002534A2 CO 2018002534 A2 CO2018002534 A2 CO 2018002534A2 CO 2018002534 A CO2018002534 A CO 2018002534A CO 2018002534 A2 CO2018002534 A2 CO 2018002534A2
- Authority
- CO
- Colombia
- Prior art keywords
- critical care
- sedation
- use during
- care treatment
- parenteral formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203748P | 2015-08-11 | 2015-08-11 | |
| US201562203731P | 2015-08-11 | 2015-08-11 | |
| US14/834,027 US9399034B1 (en) | 2015-08-11 | 2015-08-24 | Methods of sedation during critical care treatment |
| US15/185,650 US9717716B2 (en) | 2015-08-11 | 2016-06-17 | Methods of sedation during critical care treatment |
| PCT/US2016/045094 WO2017027249A1 (en) | 2015-08-11 | 2016-08-02 | Methods of sedation and parenteral formulation for use during critical care treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018002534A2 true CO2018002534A2 (es) | 2018-05-31 |
Family
ID=59687449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0002534A CO2018002534A2 (es) | 2015-08-11 | 2018-03-09 | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180235942A1 (OSRAM) |
| EP (1) | EP3334427A4 (OSRAM) |
| JP (1) | JP6857647B2 (OSRAM) |
| KR (1) | KR20180048707A (OSRAM) |
| CN (1) | CN108135889A (OSRAM) |
| AU (1) | AU2016304737B2 (OSRAM) |
| CA (1) | CA2994952A1 (OSRAM) |
| CO (1) | CO2018002534A2 (OSRAM) |
| IL (1) | IL257296B2 (OSRAM) |
| MX (1) | MX394213B (OSRAM) |
| PE (1) | PE20181332A1 (OSRAM) |
| TW (1) | TWI763632B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| EP3833351A4 (en) | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING |
| BR112021009944A2 (pt) | 2018-11-21 | 2021-08-17 | Certego Therapeutics Inc. | gaboxadol para reduzir risco de suicídio e alívio rápido de depressão |
| KR20210105387A (ko) | 2018-12-17 | 2021-08-26 | 오비드 테라퓨틱스 인크. | 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용 |
| JP2023526439A (ja) | 2020-05-20 | 2023-06-21 | セルテゴ セラピューティクス インコーポレイテッド | 精神障害の処置のための環重水素化ガボキサドールおよびその使用 |
| US20220218740A1 (en) * | 2020-10-25 | 2022-07-14 | Vaporworks Nursing Anesthesia Inc. | Opioid-free compositions for anesthesiological applications and related methods and systems |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
| WO2005063248A1 (en) * | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| ATE454140T1 (de) * | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| US9399034B1 (en) * | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2016
- 2016-08-02 AU AU2016304737A patent/AU2016304737B2/en not_active Ceased
- 2016-08-02 JP JP2018506932A patent/JP6857647B2/ja not_active Expired - Fee Related
- 2016-08-02 CN CN201680059253.3A patent/CN108135889A/zh active Pending
- 2016-08-02 KR KR1020187007146A patent/KR20180048707A/ko not_active Withdrawn
- 2016-08-02 CA CA2994952A patent/CA2994952A1/en active Pending
- 2016-08-02 EP EP16835628.5A patent/EP3334427A4/en not_active Withdrawn
- 2016-08-02 MX MX2018001720A patent/MX394213B/es unknown
- 2016-08-02 PE PE2018000199A patent/PE20181332A1/es not_active Application Discontinuation
- 2016-08-02 US US15/751,680 patent/US20180235942A1/en not_active Abandoned
- 2016-08-10 TW TW105125498A patent/TWI763632B/zh not_active IP Right Cessation
-
2018
- 2018-02-01 IL IL257296A patent/IL257296B2/en unknown
- 2018-03-09 CO CONC2018/0002534A patent/CO2018002534A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016304737B2 (en) | 2021-03-11 |
| JP6857647B2 (ja) | 2021-04-14 |
| IL257296A (en) | 2018-03-29 |
| EP3334427A4 (en) | 2019-02-06 |
| US20180235942A1 (en) | 2018-08-23 |
| CA2994952A1 (en) | 2017-02-16 |
| CN108135889A (zh) | 2018-06-08 |
| IL257296B (en) | 2022-10-01 |
| TW201717944A (zh) | 2017-06-01 |
| AU2016304737A1 (en) | 2018-02-22 |
| KR20180048707A (ko) | 2018-05-10 |
| MX2018001720A (es) | 2018-09-06 |
| TWI763632B (zh) | 2022-05-11 |
| MX394213B (es) | 2025-03-24 |
| PE20181332A1 (es) | 2018-08-20 |
| EP3334427A1 (en) | 2018-06-20 |
| JP2018522920A (ja) | 2018-08-16 |
| IL257296B2 (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018002534A2 (es) | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| CY1122671T1 (el) | Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων | |
| CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| MX385122B (es) | Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica. | |
| CL2016003260A1 (es) | Profármacos de gemcitabina | |
| PE20191407A1 (es) | Uso de gaboxadol en el tratamiento de tinnitus | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| HUE058151T2 (hu) | Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra | |
| MX2019014024A (es) | Tratamiento de los trastornos depresivos. | |
| CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
| MX381617B (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| DOP2017000014A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη |